ArticleScientific reports2025
Comparative analysis of cutaneous features of psoriasis in acute and chronic imiquimod-induced mouse models.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transdermal Transport of a Geometric Self-Oscillating Copper Nanosystem for Topical Treatment of Psoriasis.AAPS PharmSciTech · 2026Article
- Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives.Nutrients · 2026Review
- Microbial Signatures of Obesity-Aggravated Psoriasis: Insights from an Imiquimod-Based Mouse Model.International journal of molecular sciences · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
Abstract
Psoriasis is a chronic inflammatory skin disorder influenced by genetic and environmental factors. The imiquimod (IMQ)-induced mouse model is widely used to study psoriasis-like skin inflammation. However, its current use is largely limited to short treatment periods. Therefore, this model predominantly reflects acute inflammation and is limited in its capacity to capture the chronic nature of psoriasis. To date, little attention has been given to the extension of IMQ treatment duration to study the characteristics of sustained inflammation. This study aimed to provide the first direct comparison between short-term (ST, 4 days) and long-term (LT, 9 weeks) IMQ treatments on cutaneous histological, molecular and functional psoriasis features and to assess their similarity with human psoriasis. Both models demonstrated similar global severity, but with distinct features: ST-IMQ treatment led to increased epidermal hyperplasia and impaired skin barrier function, while LT-IMQ treatment was associated with greater desquamation and impaired suprabasal differentiation. Dermal mechanical properties and endothelial dysfunction were similar between the two models. Gene expression analysis revealed differentially expressed psoriasis-related markers between ST- and LT-IMQ treatments, with both models showing similarities to human psoriasis. These findings offer critical insights into how acute and chronic models can be tailored to study specific psoriasis features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.